Professor Nick La Thangue, Chief Executive Officer
Nick has extensive experience of cancer drug development and has founded several companies, including Prolifix and Celleron Therapeutics and more recently Oxford Cancer Biomarkers. He has extensive commercial experience in the biotechnology and pharmaceutical sectors.
He is a fellow of the Royal Society of Edinburgh, a member of the European Molecular Biology Organisation (EMBO), A Fellow of the Academy of Medical Sciences, a Fellow of the Lister Institute and Professorial Fellow at Linacre College Oxford. Nick is Chair of Cancer Biology at the University of Oxford.
Professor David Kerr CBE, Chief Medical Officer
David has an international reputation for the treatment of and research into colorectal cancer and his work has been awarded with several international prizes He is Professor of Cancer Medicine, University of Oxford, and Honorary Professor at Weill-Cornell College of Medicine, New York; 2nd Military University of Shanghai; Xiamen University, China; Seoul National University, Korea. He is a Fellow of the Royal Colleges of Physicians (London, Glasgow and Edinburgh), an Honorary Fellow of the Royal College of General Practitioners, a Founding Fellow of European Academy of Cancer Sciences, Past President of the European Society of Medical Oncology(2009-11) and Fellow of the Academy of Medical Sciences.
Dr John Whittaker, Chief Operating Officer
John has over 30 years experience in cancer drug development and clinical research. He was previously UK General Manager and Country Manager, Israel, at Kendle International and Director Global Clinical Development. Prior to that, he was Director, Clinical Operations (Europe) for SEQUUS Pharmaceuticals and ALZA International and Director of Oncology, at ICON Clinical Research. His PhD was in genetic toxicology and he was a post-doctoral research fellow at the Sir William Dunn School of Pathology, Oxford University. He has an MBA and has held senior positions with a number of Pharmaceutical and Clinical Research Organisations.
Bill Fleming, Chief Financial Officer
Bill’s career spans over 25 years in a broad range of finance positions. Holding a law degree from Cambridge University and as a qualified ACMA, Bill has accumulated international FD/CFO experience in small venture-backed companies and large blue chips.
Bill served as European Finance Director for Visible Genetics, a pioneering company in the field of nucleic acid diagnostics, subsequently holding senior finance positions for Bayer Healthcare in Europe and the USA. Bill played a leading role in securing investment for Oxford University spinout Oxitec and in its successful acquisition by Intrexon Corporation.